I own PSTI but rarely post anymore
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Rubicon Technology to Showcase Large-Diameter Patterned Sapphire Substrates (PSS) for the LED Market at LED Korea 2014
http://ih.advfn.com/p.php?pid=nmona&article=61042479&symbol=RBCN
Watch the movie "Wag the Dog" and learn something about the way the real world works.
Perception is everything in the stock market (especially when you do not have actual earnings)
The NNVC hit piece was only effective because of the company's license/patents structure and the three layers of protection (protection for insiders). There are other ways to restructure the patents that are friendlier to the common shareholders and still offer poison pill takeover protection for insiders.
NNVC has not responded effectively to the hit piece. The damage has been done and suing the author will not bring back the stock price and will continue to drag out with (bad) press reminders, even if NNVC wins. The last four "news" releases are all lawsuits and this also plays into the shorts hand as it is a detriment to new potential investors, so the sooner we can put those behind us the better.
The stock can still recover quickly IF management acts to plug up this "perceived hole" that will come back and bite us on a seasonal basis until it is fixed. Insiders buying stock will not work this time because insiders already control too much for wallstreets liking (this is the perceived problem that insiders control NNVC stock and also have controlling interests in their other companies license/patents).
This is why they need to combine all the companies and restructure the poison pill to benefit all shareholders ASAP to make it crystal clear that ALL investors will benefit if the technology gets approval.
You can argue the details but you cannot argue with the stock price - that is 100% perception. IMHO
CONMED Corporation Fourth Quarter 2013 Financial Results Exceed Company Guidance
http://ih.advfn.com/p.php?pid=nmona&article=61052728
Wabtec Signs Agreement To Acquire Fandstan, A Leading Rail/Industrial Equipment Manufacturer
http://ih.advfn.com/p.php?pid=nmona&article=61030886
BIOLASE Comments on $5 Million Private Placement With Oracle Investment Management, Inc.
Nice timing. I like the dead boards they are easier to follow - lol
Nice. Solar patents. I like it.
Back to hibernation.
BIOLASE Raises $5 Million in Private Placement $BIOL
http://ih.advfn.com/p.php?pid=nmona&article=61011901&symbol=BIOL
While I agree that DCVax-L will help overcome the effects of chemo, I believe that down the road further study will prove that recovery will be improved without secondary chemo treatments. JMHO BWDIK
There was nothing new in that "article" but there are always two ways to present facts and then put the negative or positive conjecture on the facts. I did not sell any NNVC today so I took the hit will all the other longs. However, I have always liked the technology and in the past have had concerns on the way the companies were structured and their insider relationships. I thought wallstreet was ok with the company structure when we uplisted. Apparently the big market boys don't do their homework and were surprised by the hatchet job.
All this doubt can be quickly put to rest by merging the two companies. I know it made sense at one time to keep them separate to avoid a hostile takeover but that time has passed. This would show that all our interests are aligned.
IDT to Exhibit Industry-leading Products at Mobile World Congress
http://ih.advfn.com/p.php?pid=nmona&article=61007224
Harris & Harris Group Notes D-Wave's Article in Time Magazine
Date : 02/10/2014 @ 8:47AM
Source : GlobeNewswire Inc.
Stock : Harris & Harris Grp., Inc. (MM) (TINY)
Quote : 3.01 0.03 (1.01%) @ 12:10PM
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, notes the article by Lev Grossman on Harris & Harris Group's portfolio company, D-Wave Systems, Inc., featured on the cover of the February 17, 2014, issue of Time Magazine. The article, titled "The Quantum Quest for a Revolutionary Computer," introduces readers to the differences between classical and quantum computing and discusses D-Wave's quantum computing technology. The article also discusses D-Wave's early customer traction and the outstanding questions around D-Wave's technology and differentiation.
A summary of the article can be viewed at content.time.com/time/magazine/article/0,9171,2164806,00.html and http://business.time.com/2014/02/06/9-ways-quantum-computing-will-change-everything/.
"D-Wave is a great example of the type of transformative companies Harris & Harris Group is involved in building," said Douglas W. Jamison, Chief Executive Officer of Harris & Harris Group. "As is often the case with disruptive technology, the emergence of commercial quantum computing has brought forward healthy dialog and ongoing research. It is exciting for Harris & Harris Group to be involved with a company disrupting how the world thinks about the future of computing."
Detailed information about Harris & Harris Group and its holdings can be found on its website at www.HHVC.com and on Facebook at www.facebook.com/harrisharrisvc.
This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012, as well as subsequent filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including, but not limited to, the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The references to the websites www.HHVC.com, www.Facebook.com, and www.Time.com have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Harris & Harris Group is not responsible for the contents of third party websites.
CONTACT: DOUGLAS W. JAMISON
(212) 582-0900
__________________________________
"Steady, As She Goes"
http://vimeo.com/38180344
If I understand it correctly, the document in question (DCVax-L IND) was actually posted as a link on NWBO's website. They changed the website and removed the link and the file. If this is true then all this talk about "stealing" is unwarranted. I'm not sure why they did this but they must have their reasons. Lets move forward please.
Innovative Dexcom G4® PLATINUM Continuous Glucose Monitor (CGM) Receives FDA Approval for Use in Children Ages 2 to 17 Years
http://ih.advfn.com/p.php?pid=nmona&article=60904541
LRAD(R) Corporation Reports Fiscal First Quarter 2014 Financial Results
http://ih.advfn.com/p.php?pid=nmona&article=60921879&symbol=LRAD
I agree. PSTI has been releasing their PR's in Israel's market time so if your not holding and BIG news hits it could gap out of sight before Nasdaq opens because it is so thin and market cap is so low. JMHO
Good to hear from you. Glad your in PSTI. Still one of my top holdings. Just a matter of time IMHO and the news thus far looks very promising. I have a bunch of projects that will keep me very busy for the next few months so I may not be on the board much. GLTA
Entegris to Acquire ATMI for $1.15 Billion
http://ih.advfn.com/p.php?pid=nmona&article=60913837
I prefer the warrants over buying the calls - NWBOW is like $5 calls with a much longer timeframe and you can use in IRA just like stock.
Excellent DD. I follow a lot of stocks and this is the best board that I follow. Great info and thoughtful civil discussion both pro and con. I admit, I don't understand the science other than on a very basic level. I invested in NWBO when I saw that insiders were funding the company with their own resources and I understood that the treatment was non-toxic and had signs of efficacy. I don't post often because I don't really have any new info or insight to offer but just want to chime in and thank everyone (several posters here have earned additional membermarks from me). Anyway, keep up the good work (back to lurking).
Does the higher volume on the upside days vs the lower volume on the retracement down days calculate into your charting? I'm not much of a trader but I like to understand what the traders view is on the stocks that I follow. Thanks again
APNT Thank you very much for your take on the chart.
Would you mind giving me your view of APNT on a chart basis? Thanks
New Sierra Wireless 4G LTE Gateway Supports Best-in-Class Business Continuity for Distributed Enterprises
http://ih.advfn.com/p.php?pid=nmona&article=60836779
$PSTI Pluristem Issues Letter to Shareholders
Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today issued a Letter to Shareholders from its CEO, Zami Aberman. The company also announced that it has launched a revised corporate website, www.pluristem.com, the content of which is not part of this press release, where investors and other interested parties can find extensive information about Pluristem and its cell therapies.
Dear Pluristem Shareholders,
We are proud to have begun 2014 with the announcement of top-line results of our Phase I/II muscle injury study. The study demonstrated safety and, with respect to the subjects treated with 150 million PLX-PAD cells, showed statistically significant improvements in its primary and secondary efficacy end points of increased muscle volume and strength when PLX-PAD cells were compared to placebo. Pluristem intends to build on these results as we plan further development of PLX-PAD cells for the orthopedic and sports injury markets. The company has also been in discussions with representatives of orthopedic companies about potential collaborations for the use of PLX-PAD in these markets.
The results of our muscle injury trial are in line with the successful outcome of our two Phase I/II clinical trials in critical limb ischemia (CLI). That trial demonstrated a significant improvement in its primary end point of amputation-free survival (AFS) when compared to historical data.
The results from these multiple clinical trials suggest that PLX-PAD cells are safe and can significantly improve patients' health. They also validate the superiority of our PLX cells and proprietary 3D culturing technology over current standard of care treatments.
2013 saw Pluristem achieve the following milestones:
Completed construction and initiated operations at our new state of the art GMP-approved facility in Haifa
Installed our 3D cell culturing systems into our new facility and demonstrated that the system implementation has maintained the quality of the PLX cell product
Consummated an out-licensing and partnership agreement with CHA Bio&Diostech for the South Korean market
Initiated a Phase I study in Pulmonary Arterial Hypertension (PAH) to be conducted in Australia with United Therapeutics
Returned to enrollment for the Phase II study in Intermittent Claudication ( IC) following the FDA's clinical hold lift
Advanced IC trials into Germany, Israel and South Korea markets in addition to the US market
Initiated and pursued efforts to introduce PLX-PAD into the preeclampsia market
Demonstrated potential efficacy in tendon injuries and in the gastrointestinal manifestations of Graft versus Host Disease (GvHD)
Increased the company's patent portfolio
Our New State-of-the-Art 3D Cell Manufacturing Facility
In January 2013 we took possession of our new state-of-the-art, good manufacturing practices (GMP) facility. This facility has the capacity to produce over 150,000 doses of PLX cells utilizing a totally automated manufacturing process that contains at its core our proprietary 3D bioreactor technology. Additionally, our new facility allows for the development of different PLX cells products, such as PLX-PAD and PLX-RAD. In 2013 we completed the comparability studies between our old and new facilities and we are currently awaiting the U.S. Food and Drug Administration's (FDA) response on our submissions. This January, Germany's health authority approved our new facility. We can now supply cells produced with our advanced, fully automated and proprietary 3D technology platform for clinical trials or commercialization of cell products, once approved, in Germany.
The CHA Bio&Diostech Agreement
We recently consummated our second out-licensing and partnership agreement with a healthcare company. Pluristem's agreement with South Korean-based CHA Bio&Diostech creates an opportunity for us to accelerate the clinical activity of our PLX cells.
The first indication agreed upon by Pluristem and CHA is in the area of Peripheral Artery Disease (PAD). CHA bears the entire cost of developing PLX cells for the indication of PAD in South Korea while Pluristem provides the cells. Upon commercialization, Pluristem and CHA Bio&Diostech will establish a 50/50 joint venture (JV) for marketing to South Korea.
We view our cooperation with CHA Bio&Diostech as long term strategic partnership. Based on the size and the opportunities of the South Korean market for PAD-related indications, we strive to expand our presence and activity in this dynamic territory. According to the research firm Clearstate, 1 million people in South Korea have PAD and the growth forecast of the disease is estimated to be moderate-to-high.
CHA will participate in our multinational Phase II IC trial which recently has been approved by the South Korean Ministry of Food and Drug Safety (MFDS). Additionally, an advanced CLI clinical trial is anticipated with CHA in South Korea.
Progress in the United Therapeutics Collaboration
Pluristem signed this out-licensing and partnership agreement with United Therapeutics in 2011 for the use of PLX-PAD cells in the treatment of Pulmonary Arterial Hypertension (PAH).
Following favorable preclinical studies, United Therapeutics received approval in April 2013 to perform a human Phase I dose escalation study in Australia using our PLX-PAD cells in patients diagnosed with PAH. The study is currently enrolling patients.
New Indications
In addition to the human Phase I and Phase II trials for the indications mentioned above, in 2013 we identified and documented potential efficacy in preclinical trials using our PLX cells for three important new indications: preeclampsia, tendon injury, and graft versus host disease (GvHD).
Independent studies conducted at the Texas A&M College of Medicine using our PLX-PAD cells in preclinical animal models of preeclampsia effectively improved several parameters of the disease. The study results were subsequently presented in May 2013 at the Society for Gynecological Investigation Summit held in Jerusalem. The potential for PLX-PAD cells to be used as a novel therapeutic for the treatment of preeclampsia is very exciting because there is currently no acceptable treatment for this potentially lethal disease, save terminating the pregnancy.
Orthopedic researchers at New York's Hospital for Special Surgery (HSS) conducted an independent study using our PLX cells in animal models of tendon injury. These studies validated our strategy to pursue the development of PLX cells for tendon injuries and represent an expansion of our orthopedic and sports injury franchise.
PLX cells have also demonstrated efficacy in the treatment of GvHD in animal models, an often lethal complication of bone marrow transplantation (BMT), with our PLX cells demonstrating a statistically significant improvement in the GvHD score versus controls. We are in discussions with a leading U.S. hematology cancer research center involving a Phase I clinical trial using our PLX-PAD cells in GvHD.
Expanded Patent Portfolio
Our intellectual property portfolio is a critical asset to our company. Pluristem was issued several U.S. and non-U.S. patents, which bring our patent count to 27 issued patents and over 100 patent applications.
Based on the achievements in the past year, we believe that Pluristem's cell therapies has the potential to become the cell therapy medicine breakthrough of the 21st century. The scientific community agrees that cell therapies hold great promise in the future of medicine. We believe that our 3D cell manufacturing platform that can produce large, commercial scale consistent batches of cells, when combined with the efficacy our cells have demonstrated to date, create a powerful combination unique to Pluristem. We've built a stronger team and a stronger company in 2013 and we look forward to achieving additional milestones and continuing to build value in 2014. The entire Pluristem team wishes you and your families a happy, healthy and prosperous 2014.
Thank you very much for your continued support.
Zami Aberman
Chairman and CEO
About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.
Pluristem has a strong intellectual property position, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions, and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.
The Pluristem Therapeutics Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6882
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, we are using forward-looking statements, when we discuss our plans to further develop PLX-PAD cells for the orthopedic and sports injury markets, when we discuss PLX-PAD cells being safe and can significantly improve patients' health, or the superiority of our PLX cells and proprietary 3D culturing technology over current standard of care treatments, when we discuss our relationship with CHA bio, how we strive to expand our presence and activity in South Korea and our planned CLI clinical trial, when we discuss our plans to pursue the development of PLX cells for new indications, when we discuss our belief that our cell therapies have the potential to become the cell therapy medicine breakthrough of the 21st century, when we discuss the powerful combination our 3D cell manufacturing platform create together with the efficacy our cells have demonstrated to date, or when we discuss our anticipation for 2014. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.
CONTACT: Pluristem Therapeutics Inc.:
Karine Kleinhaus, MD, MPH
Director of Investor Relations
1-914-512-4109
karinek@pluristem.com
Daya Lettvin
Investor & Media Relations Director
+972-54-674-5580
daya@pluristem.com
http://ih.advfn.com/p.php?pid=nmona&article=60844935
POSITIVE SPINAL DISC REPAIR TRIAL RESULTS USING MESOBLAST ADULT STEM CELLS
http://ih.advfn.com/p.php?pid=nmona&article=60844935
I was in APNT before your pick and I am still in with high hopes for the new CEO to take advantage of their incredible patented technologies. I'm not much of a trader but your timing was very good. Congratulations on your second pick too.
"Applied DNA Sciences' Dr. James A. Hayward is Network Magazine David Award Honoree
'Can David Slay the Counterfeiting Goliath?'
Looks interesting. Why did this article not make the news wires?
Manufacturing Approval for Pluristem Facility
http://finance.yahoo.com/news/manufacturing-approval-pluristem-facility-215006701.html
Scott E. Rickert, Ph.D.
Co-Founder, Chief Executive Officer and President, Nanofilm Ltd.
http://investing.businessweek.com/research/stocks/private/person.asp?personId=100472620&privcapId=51783553&previousCapId=51783553&previousTitle=Nanofilm%20Ltd.
http://www.nanofilmtechnology.com/about_nanofilm/bio-scott.htm
Dr. Rickert is one of Nanofilm's original founders. He was responsible for the original concepts that launched Nanofilm into the nanotechnology arena. Dr. Rickert was instrumental in the development of the company's first coating called "Clarity" and continues to set the vision for the company. Dr. Rickert brings a depth of research expertise to the company from his strong academic background; he was a Professor at Case Western Reserve University from 1980 to 1987. He holds a B.S. from Cornell University and a Ph.D. from Case Western Reserve University. He currently holds positions on a number of key industry groups, including the Global Advisory Board of the NanoBusiness Alliance. Dr. Rickert frequently lectures and writes on topics in the field. Dr Rickert really enjoys developing technical and distribution partnerships which allows new Nanofilm formulas to be created that are both very valuable and widely distributed.
__________________________
Scott Rickert
Founder, president and CEO, Nanofilm Ltd.
By TOM JACKSON
4:30 am, August 20, 2005
Nanofilm Ltd. founder Scott Rickert, 51, says there are two ways to develop a nanotechnology company - the Cleveland way and everyone else's way.
The Cleveland way, or more appropriately, the "Northeast Ohio way," Mr. Rickert says, is to develop a product immediately to produce cash flow and make a company viable in the marketplace.
The other way is to rely on grants, he said.
"There are very few periods of time in Nanofilm's history that we have lost money," Mr. Rickert said proudly. He is Nanofilm' s president and CEO.
Based in Valley View, Nanofilm specializes in placing thin coatings on glass and optical surfaces. Its first products were coatings to keep eyeglasses clean and help them to resist scratches.
More recently, Nanofilm has expanded into coatings to protect the windshields of cars and boats. One of its products, the Clarity Defender, prevents splattered bugs and substances such as rain and bird droppings from clinging to windshields. High-tech magazines such as Wired have noticed it, and it sells on Amazon for about $15.
The company is working hard to get the product on store shelves, a task that is more important to him than developing new products right now.
"Our focus here has to be on getting people aware of the products and their value," Mr. Rickert said.
To aid those efforts, the company hired John Swett, a former employee of the fibers, additives and rubber division of Bayer Corp. in Akron, to aid with Nanofilm's marketing. Mr. Swett said he is working to get national retail chains and automotive supply stores to carry Clarity Defender.
Mr. Swett said he was attracted to work at Nanofilm by Mr. Rickert's track record. "Somebody who has a profitable business in the nano-technology business speaks for itself," he said. "It is very exciting to come to work every day."
Mr. Swett said a possible source of new product development for Nanofilm will be films to protect the displays on devices such as cell phones and personal digital assistants. People rely upon such devices, and they don't want to look at scratched-up, dirty screens.
"People are going to want to see those problems go away," Mr. Swett said.
Sales in the first quarter of 2005 were strong, Mr. Rickert said. He declined to release figures but said sales "were across the board very high" in optical and automotive products.
"Nanofilm is in a good stage in its life to grow," he said.
Mr. Rickert was a professor at Case Western Reserve University about 20 years ago when he decided to leave and start his own company. "Most of my colleagues thought I was crazy, especially since I had just gotten tenure," he said.
But he had made up his mind that if he didn't start the company, no one would know if his technology for covering surfaces with very thin films could be turned into a commercial product. "I think that's the big thing. If I didn't do it, nobody was going to do it," he said.
Nanofilm has about 70 employees. That number has been steady for about the last two years, but Mr. Rickert contends "there's no relationship between success and the number of people you have.
It bothers Mr. Rickert that many people worry about job numbers in Northeast Ohio. In other areas of the country such as Silicon Valley, the measure of success is whether new companies are being created, he said.
"I don't know anywhere else that focuses on job count as a measure of success," he said.
Scott Rickert
Photo credit: MARC GOLUB
PRINTED FROM: http://www.crainscleveland.com/apps/pbcs.dll/article?AID=200550617010&template=printart
________________________
Seven Words of Advice for EPA Chief Gina McCarthy
A little wisdom to help develop a partnership between the new EPA and the nanotechnology community.
Mar. 14, 2013 Scott E. Rickert | IndustryWeek
http://www.industryweek.com/emerging-technologies/seven-words-advice-epa-chief-gina-mccarthy
Mesoblast Is No Match For Pluristem's IP And Manufacturing
http://seekingalpha.com/article/1948831-mesoblast-is-no-match-for-pluristems-ip-and-manufacturing
LRAD(R) Corporation Receives $4.0 Million Perimeter/Border Security Order for LRAD 2000X Systems from a Middle Eastern Countr...
http://ih.advfn.com/p.php?pid=nmona&article=60820882
The current Nanofilm, Ltd CEO Scott Rickert will be our new CEO (the company that is reverse merging into APNT).
Watch this video.
http://www.nanofilmtechnology.com/news/index.aspx
One of APNT projects that I think is most promising the the working agreement with Solexel one of Kleiner Perkins investments in solar.
http://www.greentechmedia.com/articles/read/Solexel-SunPower-Backed-Thin-Silicon-Startup-Gets-14.8M-in-VC
This is my understanding too but who wants to pay Samaung (their competitor) to make TV's for them? I'm sure some of the minor companies that have very small R&D will, but the Sony's and Panasonic's etc will probably not want to "feed" the business to Samsung as long-term they will be cutting their own throats. I'm glad APNT has many, many other irons in the fire besides the cutting edge TV market, but I would still like to see this tech advance because I want one of those TV's that won the rave reviews at CES many years ago. The tech shows me that we have the top tier engineers who are able to patent the next generation of technological advances in many other fields. Now hopefully our new CEO can get the tech into the market.